Guardian Capital (Canada)’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26.6M | Buy |
105,866
+7,306
| +7% | +$1.57M | 0.65% | 45 |
|
|
2026
Q1 | $21.4M | Buy |
98,560
+18,860
| +24% | +$4.18M | 0.57% | 49 |
|
|
2025
Q4 | $18.2M | Sell |
79,700
-2,828
| -3% | -$644K | 0.54% | 47 |
|
|
2025
Q3 | $19.1M | Buy |
82,528
+5,903
| +8% | +$1.2M | 0.62% | 47 |
|
|
2025
Q2 | $14.2M | Buy |
76,625
+1,771
| +2% | +$329K | 0.5% | 52 |
|
|
2025
Q1 | $15.7M | Sell |
74,854
-106
| -0.1% | -$20.6K | 0.62% | 49 |
|
|
2024
Q4 | $13.3M | Buy |
74,960
+1,087
| +1% | +$200K | 0.5% | 54 |
|
|
2024
Q3 | $14.6M | Sell |
73,873
-412
| -0.6% | -$76.9K | 0.53% | 49 |
|
|
2024
Q2 | $12.7M | Sell |
74,285
-179
| -0.2% | -$29.7K | 0.48% | 50 |
|
|
2024
Q1 | $13.6M | Buy |
74,464
+13
| +0% | +$2.24K | 0.47% | 50 |
|
|
2023
Q4 | $11.5M | Sell |
74,451
-776
| -1% | -$113K | 0.41% | 55 |
|
|
2023
Q3 | $11.2M | Sell |
75,227
-11,565
| -13% | -$1.7M | 0.42% | 55 |
|
|
2023
Q2 | $11.7M | Sell |
86,792
-825
| -0.9% | -$121K | 0.37% | 57 |
|
|
2023
Q1 | $14M | Buy |
87,617
+51
| +0.1% | +$7.8K | 0.45% | 54 |
|
|
2022
Q4 | $14.2M | Sell |
87,566
-226
| -0.3% | -$34.7K | 0.47% | 51 |
|
|
2022
Q3 | $11.8M | Buy |
87,792
+40,404
| +85% | +$5.8M | 0.41% | 54 |
|
|
2022
Q2 | $7.26M | Buy |
+47,388
| New | +$7.24M | 0.22% | 73 |
|
|
2019
Q1 | – | Sell |
-73,238
| Closed | -$6.75M | – | 182 |
|
|
2018
Q4 | $6.75M | Sell |
73,238
-55,084
| -43% | -$4.84M | 0.14% | 82 |
|
|
2018
Q3 | $12.1M | Sell |
128,322
-55,372
| -30% | -$5.25M | 0.2% | 68 |
|
|
2018
Q2 | $17M | Sell |
183,694
-2,087
| -1% | -$204K | 0.29% | 49 |
|
|
2018
Q1 | $17.6M | Buy |
185,781
+3,480
| +2% | +$382K | 0.3% | 52 |
|
|
2017
Q4 | $17.6M | Sell |
182,301
-896
| -0.5% | -$84.4K | 0.26% | 58 |
|
|
2017
Q3 | $16.3M | Buy |
183,197
+699
| +0.4% | +$53.2K | 0.24% | 63 |
|
|
2017
Q2 | $13.2M | Sell |
182,498
-5,747
| -3% | -$386K | 0.21% | 72 |
|
|
2017
Q1 | $12.3M | Sell |
188,245
-1,309
| -0.7% | -$82.3K | 0.19% | 74 |
|
|
2016
Q4 | $11.9M | Sell |
189,554
-2,267
| -1% | -$138K | 0.18% | 74 |
|
|
2016
Q3 | $12.1M | Sell |
191,821
-7,489
| -4% | -$485K | 0.19% | 67 |
|
|
2016
Q2 | $12.3M | Sell |
199,310
-5,749
| -3% | -$350K | 0.2% | 67 |
|
|
2016
Q1 | $11.7M | Sell |
205,059
-6,669
| -3% | -$372K | 0.2% | 70 |
|
|
2015
Q4 | $12.5M | Buy |
211,728
+14,392
| +7% | +$829K | 0.24% | 67 |
|
|
2015
Q3 | $10.7M | Buy |
197,336
+4,070
| +2% | +$265K | 0.2% | 65 |
|
|
2015
Q2 | $13M | Buy |
193,266
+16,438
| +9% | +$1.07M | 0.22% | 61 |
|
|
2015
Q1 | $10.4M | Sell |
176,828
-685
| -0.4% | -$41.4K | 0.18% | 64 |
|
|
2014
Q4 | $11.6M | Buy |
177,513
+13,615
| +8% | +$858K | 0.19% | 60 |
|
|
2014
Q3 | $9.47M | Buy |
163,898
+3,006
| +2% | +$167K | 0.14% | 71 |
|
|
2014
Q2 | $9.08M | Sell |
160,892
-3,547
| -2% | -$186K | 0.13% | 77 |
|
|
2014
Q1 | $8.45M | Buy |
164,439
+25,377
| +18% | +$1.28M | 0.13% | 79 |
|
|
2013
Q4 | $7.34M | Buy |
+139,062
| New | +$6.83M | 0.12% | 79 |
|
Other funds holding ABBV
Guardian Capital (Canada)'s ABBV Position: Q2 2026 in Review
Guardian Capital (Canada) increased its AbbVie (ABBV) stake by 7.4% in Q2 2026, buying an estimated $1.57M and bringing the position to 105,866 shares worth $26.6M. The position accounts for 0.65% of the portfolio, ranked #45.
Guardian Capital (Canada) first reported a position in ABBV in Q4 2013 and has held it in 38 quarters since. 4,063 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Guardian Capital (Canada) held 105,866 shares of AbbVie worth $26.6M as of Q2 2026.
- Guardian Capital (Canada) bought 7,306 AbbVie shares in Q2 2026, an estimated $1.57M.
- AbbVie made up 0.65% of Guardian Capital (Canada)'s portfolio in Q2 2026, its #45 holding.
- Guardian Capital (Canada) first reported a position in AbbVie in Q4 2013 and has held it in 38 quarters since.
- 4,063 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Guardian Capital (Canada)'s 13F filing for Q2 2026, filed 14 Aug 2026.